Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 7/20 | 0.92 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.68 |
| ▸ | BCAT2 | O15382 | 2/20 | 0.58 |
| ▸ | CD74 | P04233 | 1/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.50 |
| ▸ | CDK14 | O94921 | 2/20 | 0.49 |
| ▸ | CCNY | Q8ND76 | 2/20 | 0.49 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.49 |
| ▸ | CBLB | Q13191 | 1/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21345573 | 0.96 | IRAK1 (1.00) | IRAK1MAP3K19BCAT2CD74MIF | |
| SCHEMBL21345600 | 0.95 | IRAK1 (0.94) | IRAK1MAP3K19BCAT2CD74MIF | |
| SCHEMBL20206093 | 0.83 | IRAK1 (1.00) | IRAK1MAP3K19BCAT2CDK14CCNY | |
| SCHEMBL20206218 | 0.81 | IRAK1 (1.00) | IRAK1MAP3K19BCAT2CDK14CCNY | |
| SCHEMBL20206219 | 0.80 | IRAK1 (1.00) | IRAK1MAP3K19BCAT2CDK14CCNY | |
| SCHEMBL20190995 | 0.78 | IRAK1 (1.00) | IRAK1MAP3K19BCAT2CDK14CCNY | |
| SCHEMBL20206248 | 0.74 | IRAK1 (0.80) | IRAK1MAP3K19BCAT2CDK14CCNY | |
| SCHEMBL23609793 | 0.74 | PARP1 (0.57) | IRAK1MAP3K19 | |
| SCHEMBL15650842 | 0.73 | BCAT2 (0.69) | IRAK1MAP3K19BCAT2CD74MIF | |
| SCHEMBL17327878 | 0.72 | TGM2 (0.63) | IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20190276426-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299257-A9 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | IRAK1, IRAK4, IRAK2 | IRAK1 1/4885MAP3K19 15/4885BCAT2 2237/4885 |
| US-10975055-B2 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | IRAK1, IRAK4, IRAK2 | IRAK1 1/4885MAP3K19 15/4885BCAT2 2237/4885 |
| US-20190276426-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND USES THEREOF | IRAK1, IRAK4, IRAK2 | IRAK1 1/4885MAP3K19 15/4885BCAT2 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.